Chiara Massa Selected Research

Chiara Massa Research Topics

Disease

31	Neoplasms (Cancer) 04/2023 - 02/2004
6	Renal Cell Carcinoma (Grawitz Tumor) 04/2023 - 06/2011
6	Melanoma (Melanoma, Malignant) 04/2023 - 01/2020
6	Breast Neoplasms (Breast Cancer) 06/2022 - 11/2013
4	Disease Progression 01/2023 - 01/2020
3	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 08/2015
2	COVID-19 10/2023 - 11/2022
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 09/2021 - 01/2020
2	Carcinogenesis 01/2020 - 08/2015
1	Triple Negative Breast Neoplasms 04/2024
1	Leukemia 04/2023
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2023
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2023
1	Human Influenza (Influenza) 11/2022
1	Microsatellite Instability 01/2022
1	Pathologic Complete Response 01/2022
1	Lung Neoplasms (Lung Cancer) 09/2021
1	Squamous Cell Carcinoma of Head and Neck 09/2020
1	Carcinoma (Carcinomatosis) 08/2015
1	Neoplasm Metastasis (Metastasis) 09/2005

Drug/Important Bio-Agent (IBA)

8	Proteins (Proteins, Gene)FDA Link 01/2023 - 02/2004
5	InterferonsIBA 04/2023 - 01/2020
5	Biomarkers (Surrogate Marker)IBA 01/2023 - 04/2013
5	MicroRNAs (MicroRNA)IBA 11/2022 - 05/2016
5	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2020
5	HLA Antigens (Human Leukocyte Antigens)IBA 08/2021 - 06/2011
4	Messenger RNA (mRNA)IBA 01/2022 - 08/2015
4	Peptides (Polypeptides)IBA 01/2020 - 02/2004
3	BiglycanIBA 01/2023 - 01/2018
3	HLA-G Antigens (HLA G)IBA 11/2022 - 06/2015
3	AntigensIBA 11/2022 - 02/2004
3	Hormones (Hormone)IBA 06/2022 - 01/2020
2	VaccinesIBA 10/2023 - 02/2004
2	Histocompatibility Antigens Class IIBA 01/2023 - 08/2020
2	Programmed Cell Death 1 ReceptorIBA 01/2023 - 01/2022
2	Glyceraldehyde-3-Phosphate Dehydrogenases (GAPD)IBA 01/2023 - 01/2020
2	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2023 - 01/2023
2	Bovine Serum AlbuminIBA 01/2023 - 01/2020
2	Complement System Proteins (Complement)IBA 01/2022 - 01/2021
2	LigandsIBA 01/2022 - 06/2011
2	Member 2 Subfamily B ATP Binding Cassette TransporterIBA 08/2020 - 01/2020
2	Surface Antigens (Surface Antigen)IBA 08/2020 - 06/2011
2	AntibodiesIBA 10/2019 - 08/2015
2	EpitopesIBA 03/2017 - 02/2004
1	durvalumabIBA 04/2024
1	Immunoglobulin G (IgG)IBA 10/2023
1	Immunoglobulin A (IgA)IBA 10/2023
1	CytokinesIBA 04/2023
1	Caspase 1 (ICE Protease)IBA 01/2023
1	Protein Isoforms (Isoforms)IBA 01/2023
1	Pattern Recognition ReceptorsIBA 01/2023
1	InterleukinsIBA 01/2023
1	Leucine (L-Leucine)FDA Link 01/2023
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2023
1	Arginine (L-Arginine)FDA Link 01/2023
1	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 01/2023
1	Transforming Growth Factor-beta Type I ReceptorIBA 01/2023
1	Proteoglycans (Proteoglycan)IBA 01/2023
1	B7-H1 AntigenIBA 01/2023
1	Small Leucine-Rich ProteoglycansIBA 01/2023
1	purineIBA 01/2023
1	avelumabIBA 01/2022
1	Cetuximab (Erbitux)FDA Link 01/2022
1	Indicators and Reagents (Reagents)IBA 01/2022
1	NivolumabIBA 09/2021
1	Histocompatibility Antigens Class IIIBA 08/2021
1	Circulating Tumor DNAIBA 01/2021
1	RNA-Binding Proteins (RNA-Binding Protein)IBA 01/2020
1	Medroxyprogesterone Acetate (Depo-Provera)FDA LinkGeneric 01/2020
1	Untranslated Regions (Untranslated Region)IBA 01/2020
1	Phenobarbital (Luminal)FDA Link 01/2020
1	ParaffinIBA 01/2020
1	Niacinamide (Nicotinamide)FDA LinkGeneric 01/2020
1	LuciferasesIBA 01/2020
1	Horseradish PeroxidaseIBA 01/2020
1	Formaldehyde (Formol)FDA Link 01/2020
1	Firefly LuciferasesIBA 01/2020
1	transporter associated with antigen processing (TAP)IBA 01/2020
1	tapasinIBA 01/2020
1	anthraceneIBA 01/2020
1	Fluorescent Dyes (Fluorescent Probes)IBA 01/2019
1	Extracellular Matrix ProteinsIBA 01/2018
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 03/2017
1	Conditioned Culture MediaIBA 12/2015
1	Transcription Factors (Transcription Factor)IBA 08/2015
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 08/2015
1	Small Interfering RNA (siRNA)IBA 08/2015
1	HLA-DR Antigens (HLA-DR)IBA 06/2015
1	Cyclic AMP Response Element-Binding Protein (Cyclic AMP-Responsive DNA-Binding Protein)IBA 11/2013
1	Neoplasm Antigens (Tumor Antigens)IBA 06/2011
1	Therapeutic UsesIBA 09/2005
1	Heat-Shock Proteins (Heat-Shock Protein)IBA 02/2004

Therapy/Procedure

12	Immunotherapy 04/2023 - 02/2004
9	Therapeutics 01/2023 - 04/2013
1	Drug Therapy (Chemotherapy) 06/2022
1	Neoadjuvant Therapy 01/2022
1	Cell- and Tissue-Based Therapy (Cell Therapy) 02/2021
1	Transplantation 12/2013